Long-acting sustained-release pharmaceutical preparation and preparation method thereof
By adopting the PLGA5050 carrier and core-shell structure design, the drug loading and release stability of the Brapiprazole microspheres are improved, and the problems of low drug loading and sudden release in the existing technology are solved, achieving stable drug release Reduced sexual and side effects.
Patent Information
- Application Number
- CN202410667802.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-29
- Filing Date
- 2024-05-28
- Publication Date
- 2024-11-29
AI Technical Summary
The current brapiprazole microspheres have low drug loading and sudden release, which leads to unstable drug release, increases the risk of side effects, and has a strong pain in administration.
By using PLGA5050 as a carrier, brapiprazole microspheres with drug loading up to 45-75% were prepared. The core-shell structure design was used, combined with the optimization of intrinsic viscosity and molecular weight, and the uniform distribution and sustained release effect of the drug were achieved.
It achieves smooth drug release, reduces the dosage and pain, extends the release cycle, is suitable for large-scale production, and reduces the risk of side effects.
Smart Images

Figure CN119033732A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medicine, and in particular to a long-acting sustained-release pharmaceutical preparation and a preparation method thereof, and more particularly to a brepazine microsphere and a preparation method thereof. Background Art
[0002] Brepirapazole is a new generation of antipsychotic drug candidate that acts on multiple receptors. It is a partial agonist of dopamine D2 receptor (improves positive and negative symptoms, cognitive impairment and depressive symptoms), a 5-HT2A receptor antagonist (improves negative symptoms, cognitive dysfunction, symptoms of depression, insomnia), an α1 adrenergic receptor antagonist (improves positive symptoms of schizophrenia), and a 5-hydroxytryptamine uptake / reuptake inhibitor (improves depressive symptoms). At the same time, it is also a partial 5-HT1A agonist (anti-anxiety and antidepressant activity) and a 5-HT7 antagonist (body temperature, circadian rhythm, learning and memory, sleep). The oral tablets of brepirazole (Rexulti), currently developed jointly by Lundbeck of Denmark and Otsuka Pharmaceutical Co., Ltd. of Japan, were first approved by the FDA in July 2015 for the treatment of schizophrenia and as an adjunct therapy for major depression with antidepressants. They were approved for marketing in Japan and Europe in April and July 2018, respectively. The drug is administered once a day. At the same time, Otsuka Pharmaceutical Co., Ltd. of Japan is developing sustained-release oral preparations and long-acting injections. The sustained-release oral preparation is administered once a week and is in the phase III clinical stage. The phase I clinical trial of the long-acting injection has been terminated. Currently, there is no long-acting preparation of brepirazole approved for marketing. However, for patients with schizophrenia, due to the special characteristics of the patients, the phenomenon of refusing or missing medication is particularly prominent. Long-acting sustained-release preparations can reduce the number of medications, reduce the relapse rate, improve patient compliance, and reduce the burden on family members and hospitals. Therefore, the development of long-acting sustained-release preparations has high clinical value.
[0003] However, the prior art discloses that the drug loading of brexpiprazole microspheres is low and there is a burst release. For example, Bangqing Wu et al. (Engineered PLGA microspheres for extended release of brexpiprazole: in vitro and in vivo studies) disclosed a brexpiprazole microsphere, the drug loading of which is only 23.79% at most; and there is a serious burst release caused by the rapid release of brexpiprazole adsorbed on the surface of the microspheres during the in vivo release process, and the blood drug concentration fluctuates greatly during the main release period, and there is a risk of increased side effects due to excessive drug concentration. Patent JP2013139441A discloses brexpiprazole microspheres and a preparation method thereof, the drug loading of the microspheres is 21.3%, the drug loading of the sustained-release microspheres is low, and there is a high dosage of the clinical drug microsphere preparation. Since the sustained-release microspheres are usually administered subcutaneously or intramuscularly, excessive dosage will greatly increase the patient's pain.
[0004] Usually, when the drug loading in the sustained-release microspheres increases, part of the drug will be present on the surface of the microspheres, causing a burst release phenomenon in the microsphere sustained-release system, leading to increased side effects of medication. Therefore, it is of great clinical significance to develop a brepazine sustained-release microsphere preparation with high drug loading, no burst release, and stable release. Summary of the invention
[0005] Researchers have found that the drug loading of brepazine microspheres in the prior art is generally low. When the prescription disclosed in the prior art is used to prepare microspheres with a higher drug loading, there is a problem of severe burst release or incomplete release. In order to solve the above problems, the inventors have prepared brepazine sustained-release microspheres with a drug loading of up to 45-75% and no burst release through a large number of exploratory studies. The blood drug concentration changes steadily during the release process in rats, and there is no release plateau period. The release period can reach 1 month. The microspheres effectively reduce the dosage by increasing the drug loading, reduce the pain of subcutaneous or muscle administration, and the microspheres have the characteristics of high sphericity, uniform drug distribution, and can adapt to large-scale production.
[0006] The technical solution for implementing the present invention is as follows:
[0007] On the one hand, the present invention provides a brepazine microsphere, the microsphere comprising brepazine and PLGA5050, PLGA5050 refers to a polymer in which the molar ratio of PL to PG is 50:50, wherein the content of brepazine is 20%-80% (such as 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 56%, 57%, 58%, 59%, 60%, 65%, 70%, 75%, 80%) of the total weight of the microsphere, and the content of PLGA5050 is 80%-20% (such as 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 44%, 43%, 42%, 41%, 40%, 35%, 30% of the total weight of the microsphere. , 25%, 20%); preferably, the content of brepizole is 45%-75% of the total weight of the microspheres, and the content of PLGA5050 is 55%-25% of the total weight of the microspheres; more preferably, the content of brepizole is 45%-70% of the total weight of the microspheres, and the content of PLGA5050 is 55%-30% of the total weight of the microspheres; particularly preferably, the content of brepizole is 45%-65% of the total weight of the microspheres, and the content of PLGA5050 is 55%-35% of the total weight of the microspheres; most preferably, the content of brepizole is 45%-60% of the total weight of the microspheres, and the content of PLGA5050 is 55%-40% of the total weight of the microspheres.
[0008] Preferably, the intrinsic viscosity of the PLGA5050 is 0.15-0.35 dl / g, and more preferably, the intrinsic viscosity of the PLGA5050 is 0.20-0.29 dl / g.
[0009] Further, in some embodiments of the present invention, the intrinsic viscosity of the PLGA5050 is 0.15-0.35 dl / g (e.g., 0.15 dl / g, 0.16 dl / g, 0.17 dl / g, 0.18 dl / g, 0.19 dl / g, 0.20 dl / g, 0.21 dl / g, 0.22 dl / g, 0.23 dl / g, 0.24 dl / g, 0.25 dl / g, 0.26 dl / g). / g, 0.27dl / g, 0.28dl / g, 0.29dl / g, 0.30dl / g, 0.31dl / g, 0.32dl / g, 0.33dl / g, 0.34dl / g, 0.35dl / g); preferably, the intrinsic viscosity of the PLGA5050 is 0.17-0.29dl / g; more preferably, the intrinsic viscosity of the PLGA5050 is 0.20-0.29dl / g.
[0010] Further, in some embodiments of the present invention, the molecular weight of the PLGA5050 is 8000-35000 (such as 8000, 9000, 10000, 14000, 15000, 17000, 18000, 19000, 20000, 21000, 22000, 23000, 24000, 25000, 30000, 32000, 33000, 34000, 35000), preferably, the molecular weight of the PLGA5050 is 14000-35000.
[0011] Furthermore, in some embodiments of the present invention, the brepizole microspheres are of a core-shell structure, wherein the core comprises brepizole, and the shell comprises PLGA5050; and the core is fully or partially encapsulated by the shell.
[0012] Furthermore, the D50 of the microspheres is 20-60 μm (such as 20 μm, 25 μm, 30 μm, 35 μm, 40 μm, 45 μm, 50 μm, 55 μm, 60 μm); the D10 of the microspheres is 10-40 μm (such as 10 μm, 15 μm, 20 μm, 25 μm, 30 μm, 35 μm, 40 μm); the D90 of the microspheres is 40-100 μm (such as 40 μm, 45 μm, 50 μm, 55 μm, 60 μm, 65 μm, 70 μm, 75 μm, 80 μm, 85 μm, 90 μm).
[0013] Furthermore, the microspheres have a D10 of 20-40 μm, a D50 of 25-45 μm, and a D90 of 40-85 μm.
[0014] Further, in some embodiments of the present invention, the average thickness of the shell is 0.5-20 μm; preferably, the average thickness of the shell is 0.5-10 μm; more preferably, the average thickness of the shell is 0.5-6 μm.
[0015] Further, in some embodiments of the present invention, the core comprises amorphous brepirazo solid; the core comprises crystalline brepirazo solid, preferably, the core comprises amorphous and crystalline brepirazo solid.
[0016] The second aspect of the present invention provides a method for preparing the brepazine sustained-release microspheres according to the first aspect, the method comprising the following steps:
[0017] ① preparing a solution containing brepazole or its salt, PLGA5050 and an organic solvent;
[0018] ② Under the condition of effectively inhibiting the evaporation of the organic solvent, mixing the solution obtained in step ① with the PVA solution to obtain an O / W emulsion; and
[0019] ③ Under the conditions that brepiraazole is precipitated in the form of spherical particles, the organic solvent in the O / W emulsion obtained in step ② is removed.
[0020] Further, in some embodiments of the present invention, the organic solvent in step ① is not limited as long as it can dissolve brepazole and PLGA5050. Examples of such organic solvents include chloroform, dichloroethane, trichloroethane, dichloromethane, carbon tetrachloride, ether, isopropyl ether, ethyl acetate, butyl acetate, benzene, toluene, xylene, acetonitrile and mixtures thereof; preferably, the organic solvent is dichloromethane.
[0021] Further, in some embodiments of the present invention, the intrinsic viscosity of PLGA5050 in step ① is 0.15-0.35 dl / g (e.g., 0.15 dl / g, 0.16 dl / g, 0.17 dl / g, 0.18 dl / g, 0.19 dl / g, 0.20 dl / g, 0.21 dl / g, 0.22 dl / g, 0.23 dl / g, 0.24 dl / g, 0.25 dl / g, 0.26 dl / g, 0.27dl / g, 0.28dl / g, 0.29dl / g, 0.30dl / g, 0.31dl / g, 0.32dl / g, 0.33dl / g, 0.34dl / g, 0.35dl / g); preferably, the intrinsic viscosity of the PLGA5050 is 0.17-0.29dl / g; more preferably, the intrinsic viscosity of the PLGA5050 is 0.20-0.29dl / g.
[0022] Furthermore, in some embodiments of the present invention, the molar ratio of PL to PG in the PLGA5050 is 50:50.
[0023] Further, in some embodiments of the present invention, the molecular weight of the PLGA5050 is 8000-35000 (such as 8000, 9000, 10000, 14000, 15000, 17000, 18000, 19000, 20000, 21000, 22000, 23000, 24000, 25000, 30000, 32000, 33000, 34000, 35000), preferably, the molecular weight of the PLGA5050 is 14000-35000.
[0024] Furthermore, in some embodiments of the present invention, the brepizole microspheres are of a core-shell structure, wherein the core comprises brepizole, and the shell comprises PLGA5050; and the core is fully or partially encapsulated by the shell.
[0025] Further, the D50 of the microsphere is 20-100 μm (such as 20 μm, 25 μm, 30 μm, 35 μm, 40 μm, 45 μm, 50 μm, 55 μm, 60 μm, 65 μm, 70 μm, 75 μm, 80 μm, 85 μm, 90 μm, 95 μm, 100 μm), preferably, the D50 of the microsphere is 25-75 μm, more preferably, the D50 of the microsphere is 25-50 μm, and most preferably, the D50 of the microsphere is 25-45 μm.
[0026] Further, in some embodiments of the present invention, the average thickness of the shell is 0.5-20 μm; preferably, the average thickness of the shell is 0.5-10 μm; more preferably, the average thickness of the shell is 0.5-6 μm.
[0027] Further, in some embodiments of the present invention, the core comprises an amorphous brexpiprazole solid.
[0028] Further, in some embodiments of the present invention, the core comprises a crystalline brepizole solid. Preferably, the core comprises an amorphous and crystalline brepizole solid.
[0029] Further, in some embodiments of the present invention, the volume weight ratio (mL / g) of the organic solvent to brepazine or its salt in step ① is 7:1-30:1 (such as 7:1, 8:1, 9:1, 10:1, 12:1, 15:1, 20:1, 23:1, 25:1, 30:1), preferably, the volume weight ratio (mL / g) of the organic solvent to brepazine or its salt is 10:1-25:1.
[0030] Further, in some embodiments of the present invention, the weight ratio of PLGA5050 to brepazine or its salt in step ① is 4:1-1:4 (such as 4:1, 3:1, 2:1, 1:1, 1:1.2, 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9, 1:2, 1:3, 1:4); preferably, the weight ratio of PLGA5050 to brepazine or its salt is 1:1-1:2; more preferably, the weight ratio of PLGA5050 to brepazine or its salt is 1:1-1:1.5.
[0031] Furthermore, in some embodiments of the present invention, the concentration of the PVA solution in step ② is 0.1%-3% (w / v) (such as 0.1%, 0.5%, 1.0%, 1.5%, 2.0%, 2.5%, 3.0%).
[0032] Furthermore, in some embodiments of the present invention, the volume ratio of the PVA solution to the organic solvent in step ② is 100:1-500:1 (such as 100:1, 133:1, 150:1, 200:1, 233:1, 250:1, 300:1, 350:1, 400:1, 450:1, 500:1), preferably, the volume ratio of the PVA solution to the organic solvent is 200:1-450:1.
[0033] Furthermore, in some embodiments of the present invention, the step ② comprises: under suitable temperature conditions, mixing the solution obtained in step ① with the PVA solution and stirring at a rotation speed R1 to obtain an O / W emulsion; preferably, the R1 is 500-6000rpm, more preferably, the R1 is 1000-6000rpm, and most preferably, the R1 is 1500-4000rpm.
[0034] Furthermore, in some embodiments of the present invention, step ③ includes stirring the O / W emulsion obtained in step ② at a certain rotation speed under suitable temperature conditions to remove the organic solvent.
[0035] Furthermore, in some embodiments of the present invention, step ③ also includes separation and freeze-drying steps.
[0036] Furthermore, in some embodiments of the present invention, no alkali is required to adjust the pH during the preparation of the microspheres. Preferably, no alkali is required to adjust the pH of the PVA solution during the preparation process. More preferably, the pH of the PVA solution is 6-7.5. Most preferably, the pH of the PVA solution is 6-7.
[0037] In yet another aspect, the present invention provides an injectable aqueous suspension, wherein the suspension protects the brepizole microspheres of the first aspect of the present invention or the brepizole microspheres prepared in the second aspect.
[0038] Furthermore, in some embodiments of the present invention, the suspension also includes a pharmaceutically acceptable carrier and water for injection. Preferably, the pharmaceutically acceptable carrier is selected from a suspending agent, a pH regulator, an isotonic regulator, and a surfactant; the suspending agent is selected from sodium carboxymethyl cellulose, polyvinyl alcohol, polyvinyl pyrrolidone, sodium alginate and glycerol; the isotonic regulator is selected from sodium chloride, glucose, mannitol and sorbitol; the surfactant is a non-ionic surfactant selected from a polysorbate series and a poloxamer series; the pH regulator is selected from citric acid, sodium hydroxide and disodium hydrogen phosphate.
[0039] Further, in some embodiments of the present invention, the amount of microspheres in the suspension is not limited, as long as the microspheres are dispersed therein.
[0040] Advantages of the present invention:
[0041] 1. The release period of the brepazine sustained-release microspheres provided by the present invention is 1-2 months, and the release period is moderate. The medication can be adjusted in time during clinical use, effectively avoiding the risk of not being able to stop the medication in time after the microspheres are taken due to an excessively long release period (3 months or more), thereby improving the safety of medication.
[0042] 2. Generally, under the premise that the particle size of the microspheres remains basically unchanged, the higher the drug loading of the microspheres, the more serious the burst release phenomenon and the faster the release rate of the microspheres. The present invention successfully prepared brepirazole microspheres using PLGA5050. Under the simulated release conditions in vitro, the higher the drug loading, the lower the release rate. The obtained sustained-release microspheres have no burst release phenomenon in vitro, and the blood drug concentration changes steadily during the release process in rats. By increasing the drug loading, the dosage can be effectively reduced, and the pain of subcutaneous or intramuscular administration can be reduced.
[0043] 3. The high-drug-loading brexpiprazole sustained-release microspheres of the present invention have a core / shell structure. The drug is mainly wrapped in the inner core polymer, and the outer layer serves as a release barrier, which can significantly reduce the burst release of the drug, and the blood drug concentration changes steadily during the release period.
[0044] 4. The preparation method of brepazine sustained-release microspheres provided by the present invention has a simple process and a stable structure, and can be industrially mass-produced. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] Figure 1 . Scanning electron microscope images of microsphere sections obtained from experimental groups 2-1 to 2-6;
[0046] Figure 2 . XRD patterns of microspheres obtained from experimental groups 2-1 to 2-6;
[0047] Figure 3 . DSC graphs of microspheres obtained from experimental groups 2-1 to 2-6;
[0048] Figure 4 . Blood drug concentration-time curve of rats in experimental groups 2-7;
[0049] Figure 5 . Blood drug concentration-time curves of rats in experimental group 1-3, experimental group 3-2, experimental group 4-1, experimental group 4-2 and experimental group 4-3;
[0050] Figure 6 . Comparative Example 1 obtained microsphere scanning electron microscope image;
[0051] Figure 7 .Scanning electron microscope image of microspheres prepared in Comparative Example 2. DETAILED DESCRIPTION
[0052] The scheme of the present invention will be explained below in conjunction with the examples. Those skilled in the art will understand that the following examples are only used to illustrate the present invention and should not be regarded as limiting the scope of the present invention. If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the art or in accordance with the product instructions are used. The reagents or instruments used without indicating the manufacturer are all conventional products that can be obtained commercially. The brepazole raw material selected for preparing microspheres herein can be crystalline or amorphous. In some embodiments of the present invention, the brepazole raw material used is crystalline.
[0053] As used herein, the term "PLGA" refers to poly(lactide-co-glycolide) or poly(lactic acid-co-glycolic acid), and "LA:GA molar ratio" or "PL to PG molar ratio" refers to the molar ratio of polylactide to glycolide in poly(lactide-co-glycolide).
[0054] The term "intrinsic viscosity" used in this article refers to the concentrated viscosity of a polymer solution when the concentration approaches zero. It means the contribution of a single molecule to the viscosity of the solution. It is a viscosity that reflects the characteristics of the polymer and its value does not change with concentration. The intrinsic viscosity of polymers can be determined by methods commonly used in the prior art, such as the capillary method, the rotating drum method, and the falling ball method.
[0055] The term "burst release" used in this article refers to the rapid release of drugs adsorbed on the surface during in vitro release tests, which is called the burst release effect. Specifically, "burst release" means that in the determination of the in vitro release curve, the prepared microspheres release more than 20% cumulatively on the first day; the release medium used in the present invention is determined experimentally, and there is a certain correlation between the release curve measured by the test method of the present invention in the release medium of the present invention and the release curve in rats. When the release medium of the present invention is used to determine the in vitro release curve, when the cumulative release of the microspheres exceeds 20% on the first day, the corresponding microspheres have large fluctuations in the blood drug concentration in rats in the early stage, resulting in unstable blood drug concentration in the body and increasing potential side effects.
[0056] The term "crystallization" used herein refers to the preparation of solid brepirazole particles distributed between the microspheres or in the microsphere preparation solution in the brepirazole microspheres, and the solid brepirazole particles may be crystalline or amorphous.
[0057] The term "theoretical drug loading" used herein refers to the weight percentage of brepizole raw material used in the total raw materials of PLGA5050 and brepizole before microsphere preparation.
[0058] The term "drug loading" used herein refers to the actual drug loading, specifically refers to the percentage of the mass of brepazole in the prepared microspheres to the total mass of the microspheres.
[0059] As used herein, the term "molecular weight of PLGA" or "molecular weight of PLGA5050" refers to the weight average molecular weight of PLGA.
[0060] The PLGA5050 used in this article was purchased from Evonik.
[0061] In the embodiments or comparative examples, the test method is as follows:
[0062] Microsphere particle size
[0063] The particle size determination methods include microscope method and laser particle size analyzer-wet method, and the detection instrument is Malvern 3000 particle size analyzer.
[0064] Microsphere morphology
[0065] 1. Polarized light microscope
[0066] After the microspheres are stirred and solidified for a certain period of time and sieved and washed with water, a small amount of samples are taken and placed under a polarizing microscope to observe the morphology of the microspheres and whether crystallization occurs.
[0067] 2. Scanning Electron Microscopy
[0068] The freeze-dried samples were prepared and then sprayed with gold, placed under a scanning electron microscope (FSEM-2, Nova 450) for observation, and photographed to observe the morphology and internal structure of the microspheres.
[0069] Among them, the observation of the internal structure of the microspheres is divided into direct structural morphology observation and changes in the internal structure of the microspheres after dissolving brepazole. 1) Direct structural morphology observation. The microspheres were frozen with liquid nitrogen and sliced with a utility knife. 2) Changes in the internal structure of the microspheres after dissolving brepazole. 10% to 20% acetic acid solution cannot dissolve PLGA, but can dissolve a small amount of brepazole. Based on this, the microspheres were first sliced with liquid nitrogen to obtain samples with cross-sections, and then acetic acid solution was added to dissolve the brepazole in the microspheres. After the brepazole was completely dissolved, the acid solution was washed off, dried at room temperature, and observed under a scanning electron microscope. Compared with the microspheres that were not acid-washed, the part missing from the cross-section is brepazole.
[0070] 3. Study on the crystal form of breprazol in microspheres
[0071] The crystal form and compatibility of brepazole and PLGA polymer in the microspheres were studied using Rigaku's Ultimal V XRD.
[0072] DSC detection was performed using DSC3 (YQ20040540) equipment in accordance with CP 2020 version Part 4 - 0661 method and 0981 method.
[0073] 4. Drug loading and encapsulation efficiency of brexpiprazole in microspheres
[0074] The drug loading amount mentioned in the present invention refers to the amount of drug loaded by the microspheres per unit weight, and the calculation formula is:
[0075] Drug loading = weight of brepizole in microspheres / (total weight of brepizole in microspheres + PLGA) × 100%.
[0076] The encapsulation efficiency of the present invention refers to the percentage of the weight of brepirazolide encapsulated in the microspheres to the weight of brepirazolide added during preparation, and the calculation formula is:
[0077] Encapsulation efficiency = weight of brepirazoline in microspheres / weight of brepirazoline added during preparation × 100%.
[0078] 5. Determination of in vitro release curve
[0079] Take an appropriate amount of sample (containing about 2 mg of breprazol), weigh it accurately, add 150 mL of release medium (2 mM potassium dihydrogen phosphate, 8 mM disodium hydrogen phosphate, 137 mM sodium chloride, 2.7 mM potassium chloride, 0.05% benzalkonium chloride, 1% Tween 80) which has been thermostatted to 37 ± 0.5 ° C, and place it in a 37 ° C thermostat drying oven and let it stand. Take 5 mL of samples at 2h, 4h, 1d, 2d, 3d, 4d, 5d, 6d, 7d, etc. (the sampling point is adjusted according to the actual release of the sample), and add 5 mL of liquid, centrifuge the sample solution, take the supernatant and use high performance liquid chromatography to detect the release amount, and then make a release curve.
[0080] Example 1
[0081] Experimental group 1-1
[0082] 0.28g of brepazole and 0.42g of PLGA were mixed, wherein the molar ratio of LA:GA of the PLGA was 50:50, the intrinsic viscosity was 0.20dl / g, and the molecular weight was 14200. 6mL of dichloromethane was added, dissolved in a water bath at 50-60°C (the temperature range was acceptable), and stirred evenly to obtain an oil phase; at the same time, a 0.5% PVA solution was prepared.
[0083] The oil phase was added to 1400 mL of 0.5% PVA aqueous solution, and homogenized and emulsified for 2 min using a disperser emulsifier at a speed of 2000 rpm. After the homogenization and emulsification, mechanical stirring was started at room temperature for room temperature curing for 5 h. A 5 mL sample was taken to observe the microsphere morphology under a microscope, and the microspheres were collected by filtration and freeze-dried.
[0084] Experimental Group 1-2
[0085] 0.35 g of brepazole and 0.35 g of PLGA were mixed, wherein the molar ratio of LA:GA of the PLGA was 50:50, the intrinsic viscosity was 0.20 dl / g, and the molecular weight was 14200. 6 mL of dichloromethane was added, dissolved in a water bath at 50-60°C (the temperature range was acceptable), and stirred evenly to obtain an oil phase; at the same time, a 0.5% PVA solution was prepared.
[0086] The oil phase was added to 1400 mL of 0.5% PVA aqueous solution, and homogenized and emulsified for 2 min using a disperser emulsifier at a speed of 2000 rpm. After the homogenization and emulsification, mechanical stirring was started at room temperature for room temperature curing for 5 h. A 5 mL sample was taken to observe the microsphere morphology under a microscope, and the microspheres were collected by filtration and freeze-dried.
[0087] Experimental Groups 1-3
[0088] 0.42 g of brepazole and 0.28 g of PLGA were mixed, wherein the molar ratio of LA:GA of the PLGA was 50:50, the intrinsic viscosity was 0.20 dl / g, and the molecular weight was 14200. 6 mL of dichloromethane was added, dissolved in a water bath at 50-60°C (the temperature range was acceptable), and stirred evenly to obtain an oil phase; at the same time, a 0.5% PVA solution was prepared.
[0089] The oil phase was added to 1400 mL of 0.5% PVA aqueous solution, and homogenized and emulsified for 2 min using a disperser emulsifier at a speed of 2000 rpm. After the homogenization and emulsification, mechanical stirring was started at room temperature for room temperature curing for 5 h. A 5 mL sample was taken to observe the microsphere morphology under a microscope, and the microspheres were collected by filtration and freeze-dried.
[0090] Experimental Groups 1-4
[0091] Mix 0.35g of brepazole and 0.15g of PLGA, wherein the molar ratio of LA:GA of the PLGA is 50:50, the intrinsic viscosity is 0.20dl / g, and the molecular weight is 14200. Add 5mL of dichloromethane, dissolve in a water bath at 50-60°C (the temperature range is acceptable), stir evenly, and obtain an oil phase; at the same time, prepare a 0.5% PVA solution.
[0092] The oil phase was added to 2000 mL of 0.5% PVA aqueous solution, and homogenized and emulsified for 2 min using a disperser emulsifier at a speed of 2000 rpm. After the homogenization and emulsification, mechanical stirring was started at room temperature for room temperature curing for 5 h. A 5 mL sample was taken to observe the microsphere morphology under a microscope, and the microspheres were collected by filtration and freeze-dried.
[0093] Experimental Groups 1-5
[0094] Mix 0.375g of brepazole and 0.125g of PLGA, wherein the molar ratio of LA:GA of the PLGA is 50:50, the intrinsic viscosity is 0.20dl / g, and the molecular weight is 14200. Add 5mL of dichloromethane, dissolve in a water bath at 50-60°C (the temperature range is acceptable), stir evenly, and obtain an oil phase; at the same time, prepare a 0.5% PVA solution.
[0095] The oil phase was added to 2000 mL of 0.5% PVA aqueous solution, and homogenized and emulsified for 2 min using a disperser emulsifier at a speed of 2000 rpm. After the homogenization and emulsification, mechanical stirring was started at room temperature for room temperature curing for 5 h. A 5 mL sample was taken to observe the microsphere morphology under a microscope, and the microspheres were collected by filtration and freeze-dried.
[0096] Experimental Groups 1-6
[0097] 0.4 g of brepazole and 0.1 g of PLGA were mixed, wherein the molar ratio of LA:GA of the PLGA was 50:50, the intrinsic viscosity was 0.20 dl / g, and the molecular weight was 14200. 5 mL of dichloromethane was added, dissolved in a water bath at 50-60°C (the temperature range was acceptable), and stirred evenly to obtain an oil phase; at the same time, a 0.5% PVA solution was prepared.
[0098] The oil phase was added to 2000 mL of 0.5% PVA aqueous solution, and homogenized and emulsified for 2 min using a disperser emulsifier at a speed of 2000 rpm. After the homogenization and emulsification, mechanical stirring was started at room temperature for room temperature curing for 5 h. A 5 mL sample was taken to observe the microsphere morphology under a microscope, and the microspheres were collected by filtration and freeze-dried.
[0099] Experimental Group 2-1
[0100] 0.20 g of brepazole and 0.80 g of PLGA were mixed, wherein the molar ratio of LA:GA of the PLGA was 50:50, the intrinsic viscosity was 0.23 dl / g, and the molecular weight was 25000. 10 mL of dichloromethane was added, dissolved in a water bath at 50-60°C (the temperature range was acceptable), and stirred evenly to obtain an oil phase; at the same time, a 0.5% PVA solution was prepared.
[0101] The oil phase was added to 2000 mL of 0.5% PVA aqueous solution, and homogenized and emulsified for 2 min using a disperser emulsifier at a speed of 2000 rpm. After the homogenization and emulsification, mechanical stirring was started at room temperature for room temperature curing for 5 h. A 5 mL sample was taken to observe the microsphere morphology under a microscope, and the microspheres were collected by filtration and freeze-dried.
[0102] Experimental group 2-2
[0103] Mix 0.40g of brepazole and 0.60g of PLGA, wherein the molar ratio of LA:GA of the PLGA is 50:50, the intrinsic viscosity is 0.23dl / g, and the molecular weight is 25000. Add 10mL of dichloromethane, dissolve in a water bath at 50-60°C (the temperature range is acceptable), stir evenly, and obtain an oil phase; at the same time, prepare a 0.5% PVA solution.
[0104] The oil phase was added to 2000 mL of 0.5% PVA aqueous solution, and homogenized and emulsified for 2 min using a disperser emulsifier at a speed of 2000 rpm. After the homogenization and emulsification, mechanical stirring was started at room temperature for room temperature curing for 5 h. A 5 mL sample was taken to observe the microsphere morphology under a microscope, and the microspheres were collected by filtration and freeze-dried.
[0105] Experimental Group 2-3
[0106] Mix 0.50 g of brepazole and 0.50 g of PLGA, wherein the molar ratio of LA:GA of the PLGA is 50:50, the intrinsic viscosity is 0.23 dl / g, and the molecular weight is 25000. Add 10 mL of dichloromethane, dissolve in a water bath at 50-60°C (the temperature range is acceptable), stir evenly, and obtain an oil phase; at the same time, prepare a 0.5% PVA solution.
[0107] The oil phase was added to 2000 mL of 0.5% PVA aqueous solution, and homogenized and emulsified for 2 min using a disperser emulsifier at a speed of 2000 rpm. After the homogenization and emulsification, mechanical stirring was started at room temperature for room temperature curing for 5 h. A 5 mL sample was taken to observe the microsphere morphology under a microscope, and the microspheres were collected by filtration and freeze-dried.
[0108] Experimental Groups 2-4
[0109] Mix 0.60g of brepazole and 0.40g of PLGA, wherein the molar ratio of LA:GA of the PLGA is 50:50, the intrinsic viscosity is 0.23dl / g, and the molecular weight is 25000. Add 10mL of dichloromethane, dissolve in a water bath at 50-60°C (the temperature range is acceptable), stir evenly, and obtain an oil phase; at the same time, prepare a 0.5% PVA solution.
[0110] The oil phase was added to 2000 mL of 0.5% PVA aqueous solution, and homogenized and emulsified for 2 min using a disperser emulsifier at a speed of 2000 rpm. After the homogenization and emulsification, mechanical stirring was started at room temperature for room temperature curing for 5 h. A 5 mL sample was taken to observe the microsphere morphology under a microscope, and the microspheres were collected by filtration and freeze-dried.
[0111] Experimental Groups 2-5
[0112] Mix 0.35g of brepazole and 0.15g of PLGA, wherein the molar ratio of LA:GA of the PLGA is 50:50, the intrinsic viscosity is 0.23dl / g, and the molecular weight is 25000. Add 5mL of dichloromethane, dissolve in a water bath at 50-60°C (the temperature range is acceptable), stir evenly, and obtain an oil phase; at the same time, prepare a 0.5% PVA solution.
[0113] The oil phase was added to 2000 mL of 0.5% PVA aqueous solution, and homogenized and emulsified for 2 min using a disperser emulsifier at a speed of 2000 rpm. After the homogenization and emulsification, mechanical stirring was started at room temperature for room temperature curing for 5 h. A 5 mL sample was taken to observe the microsphere morphology under a microscope, and the microspheres were collected by filtration and freeze-dried.
[0114] Experimental Groups 2-6
[0115] Mix 0.40g of brepazole and 0.10g of PLGA, wherein the molar ratio of LA:GA of the PLGA is 50:50, the intrinsic viscosity is 0.23dl / g, and the molecular weight is 25000. Add 5mL of dichloromethane, dissolve in a water bath at 50-60°C (the temperature range is acceptable), stir evenly, and obtain an oil phase; at the same time, prepare a 0.5% PVA solution.
[0116] The oil phase was added to 2000 mL of 0.5% PVA aqueous solution, and homogenized and emulsified for 2 min using a disperser emulsifier at a speed of 2000 rpm. After the homogenization and emulsification, mechanical stirring was started at room temperature for room temperature curing for 5 h. A 5 mL sample was taken to observe the microsphere morphology under a microscope, and the microspheres were collected by filtration and freeze-dried.
[0117] Experimental Groups 2-7
[0118] Mix 0.42g of brepazole and 0.28g of PLGA, wherein the molar ratio of LA:GA of the PLGA is 50:50, the intrinsic viscosity is 0.23dl / g, and the molecular weight is 25000. Add 6mL of dichloromethane, dissolve in a water bath at 50-60°C (the temperature range is acceptable), stir evenly, and obtain an oil phase; at the same time, prepare a 0.5% PVA solution.
[0119] The oil phase was added to 1400 mL of 0.5% PVA aqueous solution, and homogenized and emulsified for 2 min using a disperser emulsifier at a speed of 2000 rpm. After the homogenization and emulsification, mechanical stirring was started at room temperature for room temperature curing for 5 h. A 5 mL sample was taken to observe the microsphere morphology under a microscope, and the microspheres were collected by filtration and freeze-dried.
[0120] Experimental Group 3-1
[0121] 0.28g of brepazole and 0.42g of PLGA were mixed, wherein the molar ratio of LA:GA of the PLGA was 50:50, the intrinsic viscosity was 0.29dl / g, and the molecular weight was 34000. 6mL of dichloromethane was added, dissolved in a water bath at 50-60°C (the temperature range was acceptable), and stirred evenly to obtain an oil phase; at the same time, a 0.5% PVA solution was prepared.
[0122] The oil phase was added to 1400 mL of 0.5% PVA aqueous solution, and homogenized and emulsified for 2 min using a disperser emulsifier at a speed of 2000 rpm. After the homogenization and emulsification, mechanical stirring was started at room temperature for room temperature curing for 5 h. A 5 mL sample was taken to observe the microsphere morphology under a microscope, and the microspheres were collected by filtration and freeze-dried.
[0123] Experimental group 3-2
[0124] 0.42 g of brepazole and 0.28 g of PLGA were mixed, wherein the molar ratio of LA:GA of the PLGA was 50:50, the intrinsic viscosity was 0.29 dl / g, and the molecular weight was 34000. 6 mL of dichloromethane was added, dissolved in a water bath at 50-60°C (the temperature range was acceptable), and stirred evenly to obtain an oil phase; at the same time, a 0.5% PVA solution was prepared.
[0125] The oil phase was added to 1400 mL of 0.5% PVA aqueous solution, and homogenized and emulsified for 2 min using a disperser emulsifier at a speed of 2000 rpm. After the homogenization and emulsification, mechanical stirring was started at room temperature for room temperature curing for 5 h. A 5 mL sample was taken to observe the microsphere morphology under a microscope, and the microspheres were collected by filtration and freeze-dried.
[0126] Experimental group 3-3
[0127] Mix 0.35g of brepazole and 0.15g of PLGA, wherein the molar ratio of LA:GA of the PLGA is 50:50, the intrinsic viscosity is 0.29dl / g, and the molecular weight is 34000. Add 5mL of dichloromethane, dissolve in a water bath at 50-60°C (the temperature range is acceptable), stir evenly, and obtain an oil phase; at the same time, prepare a 0.5% PVA solution.
[0128] The oil phase was added to 2000 mL of 0.5% PVA aqueous solution, and homogenized and emulsified for 2 min using a disperser emulsifier at a speed of 2000 rpm. After the homogenization and emulsification, mechanical stirring was started at room temperature for room temperature curing for 5 h. A 5 mL sample was taken to observe the microsphere morphology under a microscope, and the microspheres were collected by filtration and freeze-dried.
[0129] Experimental Group 3-4
[0130] Mix 0.40g of brepazole and 0.10g of PLGA, wherein the molar ratio of LA:GA of the PLGA is 50:50, the intrinsic viscosity is 0.29dl / g, and the molecular weight is 34000. Add 5mL of dichloromethane, dissolve in a water bath at 50-60°C (the temperature range is acceptable), stir evenly, and obtain an oil phase; at the same time, prepare a 0.5% PVA solution.
[0131] The oil phase was added to 2000 mL of 0.5% PVA aqueous solution, and homogenized and emulsified for 2 min using a disperser emulsifier at a speed of 2000 rpm. After the homogenization and emulsification, mechanical stirring was started at room temperature for room temperature curing for 5 h. A 5 mL sample was taken to observe the microsphere morphology under a microscope, and the microspheres were collected by filtration and freeze-dried.
[0132] Comparison group 1
[0133] Mix 0.30 g of brepazole and 0.20 g of PLGA, wherein the molar ratio of LA:GA of the PLGA is 50:50, the intrinsic viscosity is 0.57 dl / g, and the molecular weight is 55800. Add 5 mL of dichloromethane, dissolve in a water bath at 50-60°C (the temperature range is acceptable), stir evenly, and obtain an oil phase; at the same time, prepare a 0.5% PVA solution.
[0134] The oil phase was added to 2000 mL of 0.5% PVA aqueous solution, and homogenized and emulsified for 2 min using a disperser emulsifier at a speed of 2000 rpm. After the homogenization and emulsification, mechanical stirring was started at room temperature for room temperature curing for 5 h. A 5 mL sample was taken to observe the microsphere morphology under a microscope, and the microspheres were collected by filtration and freeze-dried.
[0135] Comparison group 2
[0136] Mix 0.35g of brepazole and 0.15g of PLGA, wherein the molar ratio of LA:GA of the PLGA is 50:50, the intrinsic viscosity is 0.57dl / g, and the molecular weight is 55800. Add 5mL of dichloromethane, dissolve in a water bath at 50-60°C (the temperature range is acceptable), stir evenly, and obtain an oil phase; at the same time, prepare a 0.5% PVA solution.
[0137] The oil phase was added to 2000 mL of 0.5% PVA aqueous solution, and homogenized and emulsified for 2 min using a disperser emulsifier at a speed of 2000 rpm. After the homogenization and emulsification, mechanical stirring was started at room temperature for room temperature curing for 5 h. A 5 mL sample was taken to observe the microsphere morphology under a microscope, and the microspheres were collected by filtration and freeze-dried.
[0138] Table 1 Particle size, theoretical drug loading, actual drug loading and encapsulation efficiency of microspheres obtained in the experimental group and the control group
[0139]
[0140]
[0141] Table 2 In vitro release of microspheres obtained in the experimental group and the control group
[0142]
[0143] Conclusion: It can be seen from Tables 1 and 2 that for PLGA5050, polymers with different viscosities can be used to prepare brepazine microspheres, but the viscosity or molecular weight of the polymer greatly affects the encapsulation efficiency and release behavior of high-drug-loaded brepazine microspheres. From comparison group 1, it can be seen that when the viscosity of PLGA5050 is 0.57 dl / g, the molecular weight is 55800, and the theoretical drug loading of brepazine is 60%, the encapsulation efficiency of the prepared microspheres is 90.5%; however, there is a release plateau during the release process, which is not conducive to future clinical commercial applications. From comparison group 2, it can be seen that when the viscosity of PLGA5050 is 0.57 dl / g, the molecular weight is 55800, and the theoretical drug loading of brepazine is 70%, the actual drug loading of the prepared microspheres is 54.0%, and the encapsulation efficiency is only 77.1%; and the early release is faster during the release process, which has the risk of increased side effects.
[0144] When PLGA5050 with a viscosity of 0.20-0.29dl / g and a molecular weight of 14000-34000 is selected as the polymer, a theoretical drug loading of 60% of brepirazole microspheres can be prepared, and the encapsulation rate is as high as 90%. The prepared microsphere particle size D50 is 36-42μm, and the particle sizes of microspheres with different drug loadings are close, with no significant difference; when the theoretical drug loading of brepirazole microspheres is increased to 70%, the encapsulation rate of the prepared microspheres is significantly reduced to below 80%, and there is an in vitro burst release phenomenon. This shows that for PLGA5050, the theoretical drug loading of brepirazole microspheres is preferably less than 70%.
[0145] Those skilled in the art generally believe that, under the premise that the particle size of the microspheres remains basically unchanged, the higher the drug loading of the microspheres, the more severe the burst release phenomenon and the faster the release rate of the microspheres. However, after systematic research, the inventor unexpectedly found that according to the prescription design of the present invention, when the drug loading of the microspheres is less than 60%, as the drug loading of the microspheres increases, the release rate of the microspheres shows a decreasing trend. Specifically, see the in vitro release experimental data of different experimental groups in Table 2.
[0146] In order to further explore the reason why the higher the drug loading of brepazine microspheres, the slower the release, the inventors further analyzed the internal structure of brepazine microspheres prepared from experimental groups 2-1 to 2-6. The freeze-dried samples were sliced, sprayed with gold, placed under a scanning electron microscope for observation, and photographed to observe the morphology and internal structure of the microspheres. The internal structure observation of the microspheres was divided into direct structural morphology observation. The scanning electron microscope images of the samples prepared from experimental groups 2-1 to 2-6 were as follows: Figure 1 shown.
[0147] At the same time, XRD and DSC tests were performed on the prepared brepazine microspheres from experimental groups 2-1 to 2-6. Figure 2 As shown, DSC Figure 3 shown.
[0148] from Figure 1 It can be seen that when the theoretical drug loading is below 20%, the microspheres prepared have evenly distributed small holes on the surface and inside, and there is no crystallization on the surface of the microspheres; when the theoretical drug loading is 40%, the microspheres prepared have evenly distributed small holes on the surface and inside, and a certain number of large holes are also distributed inside the microspheres, and there is no crystallization on the surface of the microspheres; when the theoretical drug loading is 50%, the prepared microspheres have obvious core-shell structure, the shell thickness is about 3-6μm, and many small holes distributed on the shell surface can be clearly seen through the electron microscope, and there are no obvious holes inside the core; when the theoretical drug loading is 60%, similar phenomena can be seen when the drug loading is 50%, the microspheres have a core-shell structure, and small holes are evenly distributed on the shell. When the theoretical drug loading of the microspheres is 70-80%, it can be seen that a large number of fine crystals are covered on the surface of the microspheres. The technicians cannot remove the crystals on the surface of the microspheres by increasing the washing time or increasing the flushing amount during the preparation process, that is, the crystals on the surface of the microspheres cannot be removed by optimizing the microsphere preparation process.
[0149] For the brepazine microspheres prepared by PLGA5050, the microsphere structure changes with the change of drug loading. The higher the drug loading, the easier it is for the PLGA5050 brepazine microspheres to form a core-shell structure. For the core-shell structure microspheres, the outer polymer needs to be dissolved to release the internal drugs. Therefore, the high-drug-loading sustained-release microspheres have no burst release in the early stage, and the release rate is slower than that of the low-drug-loading sustained-release microspheres. When the theoretical drug loading of the microspheres exceeds 70%, PLGA5050 interacts with brepazine, causing brepazine to be deposited on the surface of the microspheres, resulting in severe burst release during the in vitro release of the prepared brepazine microspheres.
[0150] Further, the preparation uses breprazol raw material as a crystalline structure, however, from Figure 2It can be seen that when the theoretical drug loading is 20-40%, the brepirazole in the prepared brepirazole microspheres is amorphous; when the theoretical drug loading is 50% and above, the brepirazole in the prepared microspheres is a mixed form of amorphous and crystalline.
[0151] from Figure 3 It can be seen that the peak corresponding to 60°C is the endothermic peak of the glass transition of brepirazole microspheres, and the peak corresponding to around 100°C-120°C is the exothermic peak of the transformation of amorphous brepirazole in brepirazole microspheres into crystalline brepirazole.
[0152] Example 2
[0153] In the field of microsphere preparation, preparation conditions have a significant impact on the sphericity of microspheres, among which the factors with the greatest impact include the ratio of the amount of organic solvent dichloromethane to the amount of brepazine, the homogenization stirring speed, the concentration of PVA aqueous phase, and the volume ratio of aqueous phase to oil phase, etc. The inventors conducted a systematic study on this series of factors.
[0154] 3.1 Effect of different microsphere particle sizes on test results
[0155] Weigh 0.6 g of brepazole and 0.4 g of PLGA, wherein the molar ratio of LA:GA of the PLGA is 50:50, the intrinsic viscosity is 0.23 dl / g, and the molecular weight is 25000. Add 10 mL of dichloromethane respectively, dissolve in a 50-60°C water bath, stir evenly to obtain an oil phase, and prepare a 0.5% concentration PVA solution.
[0156] The oil phase was added to 2000 mL of PVA aqueous solution respectively, and homogenized and emulsified for 2 min at different speeds using a disperser emulsifier. After the homogenization and emulsification, the room temperature was controlled at about 25°C, mechanical stirring was turned on for room temperature curing for 5 h, and 5 mL of sample was taken to observe the microsphere morphology under a microscope. The microspheres were collected by filtration and freeze-dried.
[0157] The particle size, drug loading, encapsulation efficiency and polarizing microscope of the microspheres obtained from Experimental Groups 4-1 to 4-3 were measured according to the method described in the examples of the specification.
[0158] Table 3
[0159]
[0160]
[0161] Conclusion: Microspheres with different particle sizes can be prepared by changing the rotation speed, and the microspheres have good sphericity.
[0162] Using the same method, the applicant found through research that for PLGA5050 brepazole microspheres, the appropriate ratio of dichloromethane volume to brepazole weight is 7-25:1 (mL / g). Under this experimental condition, the experiment was carried out smoothly and efficiently, and the obtained microspheres had good morphology and uniform size. When the ratio of dichloromethane volume to brepazole weight was 4.3:1, dichloromethane could not completely dissolve brepazole; when the ratio of dichloromethane volume to brepazole weight was 5.7:1, dichloromethane could completely dissolve brepazole, but the dissolution time would be longer.
[0163] For PLGA5050 brepazine microspheres, the PVA concentration has little effect on the microspheres. The applicant uses a univariate research method and selects PVA with a concentration of 0.1-3%, and can prepare spherical brepazine microspheres. There is no crystallization in the prepared microspheres. Polarized light microscopy or scanning electron microscopy observation shows that the prepared microspheres are uniformly spherical, with a smooth surface and no damage or breakage.
[0164] For PLGA5050 brexpiprazole microspheres, when the theoretical drug loading is less than 60%, the appropriate range of the volume ratio of PVA solution to dichloromethane is 150:1-200:1. When the volume ratio of PVA solution to dichloromethane is less than 150:1, the prepared microspheres have more crystallization; when the theoretical drug loading is greater than 60%, the appropriate range of the volume ratio of PVA solution to dichloromethane is 400:1-600:1. When the volume ratio of PVA solution to dichloromethane is less than 300:1, there are more crystallizations during the preparation of microspheres.
[0165] Example 3
[0166] The brepazine microspheres prepared by the experimental groups 1-3, 2-7, 3-2, 4-1, 4-2 and 4-3 of the present invention were prepared into preparations, and the specific method was as follows: a certain amount of microspheres were weighed and dispersed with a prepared suspension (CMC-Na 0.6wt%, sodium chloride 0.75wt%, anhydrous citric acid 0.11wt%, sodium hydroxide 0.055wt%, disodium hydrogen phosphate 0.1wt%). The suspension was prepared to have a brepazine solution concentration ratio of 15mg / mL.
[0167] The sample was injected into the hind leg muscle of SD rats, among which the dose of experimental group 1-3 was 30 mg / kg; the dose of experimental group 2-7, experimental group 3-2, experimental group 4-1, experimental group 4-2 and experimental group 4-3 was 45 mg / kg. Blood samples were collected before administration (pre-dose), 6h (0.25d), 24h (1d), 3d, 5d, 7d, 10d, 14d, 19d, 24d, 28d, 35d, 42d, 49d, 56d, 63d, 70d, 77d and 84d after administration. The drug concentration in plasma was determined by the established LC-MS method, the blood drug concentration and time curve of rats were plotted, and the blood drug concentration-time relationship was evaluated.
[0168] The results of experimental groups 2-7 are shown in Figure 4 As shown; Experimental Group 1-3, Experimental Group 3-2, Experimental Group 4-1, Experimental Group 4-2 and Experimental Group 4-3 currently have 28-day sampling results, the results are shown in Figure 5 shown.
[0169] The blood drug concentration of rats in experimental groups 2-7 changed steadily during the release cycle, and the blood drug concentration remained within the effective concentration range during administration, with an effective period of up to 30 days. After the 35th day, the blood drug concentration dropped to nearly 0, and there was no obvious peak-valley phenomenon during the entire release cycle.
[0170] Experimental groups 1-3, 3-2, 4-1, 4-2 and 4-3 can all maintain effective drug release concentrations within the current 28-day detection period. Among them, experimental group 4-3 had a blood drug concentration peak on the 5th day of drug release due to its smaller particle size. The blood drug concentrations of other samples have remained stable within the current release period.
[0171] Comparative Example
[0172] Comparative Example 1
[0173] According to the method of Example 1 of patent CN108498456A, brepazole microspheres were prepared. Specifically, brepazole 0.5g and PLGA 0.2g were mixed, wherein the polylactide-glycolide copolymer was 0.23dL / g, the weight-average molecular weight was 25000, and the molar ratio of polylactide to glycolide was 50:50. 3.01mL of dichloromethane was added and mixed, and the heating temperature was 55°C and the mixture was shaken and dissolved. At the same time, 620mL of 1% PVA solution was prepared, sodium hydroxide was added to adjust the pH to 10, the temperature was controlled to 12°C, and the solvent was dispersed in the outer PVA solution using a high-speed emulsifier or static mixer at a speed of 3000rpm. After curing for 3 hours, the microspheres were collected by filtration and freeze-dried. A 5mL sample was taken to observe the microsphere morphology under a microscope, the microspheres were collected by filtration, and freeze-dried. The measured drug loading of the microspheres was 59.4%, and the encapsulation efficiency was 83.7%. When brepazole microspheres were prepared using this method, brepazole could not be completely dissolved. The prepared breprazol microspheres have a large number of fine crystals and a small amount of large crystals before sieving, and the prepared microspheres have poor sphericity. The electron microscopy image of the microspheres is as follows Figure 6 shown.
[0174] Comparative Example 2
[0175] According to the method of Example 1 of patent CN108498456A, brepirazole microspheres were prepared. Due to the difference in properties between brepirazole and aripiprazole, in order to better dissolve brepirazole, the amount of dichloromethane and the corresponding PVA solution was increased. Specifically, 0.5g of brepirazole and 0.2g of PLGA were mixed, wherein the polylactide-glycolide copolymer was 0.23dL / g, the weight-average molecular weight was 25000, and the molar ratio of polylactide to glycolide was 50:50. 6mL of dichloromethane was added and mixed, and the heating temperature was 55°C and shaken to dissolve. At the same time, 2400mL of 1% PVA solution was prepared, sodium hydroxide was added to adjust the pH to 10, the temperature was controlled to 12°C, and a high-speed emulsifier or static mixer was used to disperse the solvent in the external PVA solution at a speed of 3000rpm. Curing for 5 hours, filtering and collecting the microspheres, freeze-drying, taking 5mL of sample to observe the microsphere morphology under a microscope, filtering and collecting the microspheres, and freeze-drying. The measured drug loading of the microspheres was 40.6%, and the encapsulation efficiency was 57.2%. When the method was used to prepare brepirazole microspheres, the brepirazole microspheres could not be completely dissolved, and the prepared brepirazole microspheres had many fine crystals before sieving, and the prepared microspheres had poor sphericity. Figure 7 shown.
[0176] When preparing brepirazole microspheres using the preparation method for preparing aripiprazole microspheres disclosed in the prior art, it is difficult to prepare brepirazole microspheres with good sphericity. This confirms that for different compounds, due to differences in their physicochemical properties, the corresponding microsphere formulations and preparation processes are quite different.
[0177] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.
[0178] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.
Claims
1. A breprazol microsphere, characterized in that: The microspheres include brepazole and PLGA5050, wherein the content of brepazole is 20%-80% of the total weight of the microspheres, and the content of PLGA5050 is 80%-20% of the total weight of the microspheres; Preferably, the content of brepazole is 45%-75% of the total weight of the microspheres, and the content of PLGA5050 is 55%-25% of the total weight of the microspheres; More preferably, the content of brepazole is 45%-65% of the total weight of the microspheres; the content of PLGA5050 is 55%-35% of the total weight of the microspheres; Most preferably, the content of brepazole is 45%-60% of the total weight of the microspheres; the content of PLGA5050 is 55%-40% of the total weight of the microspheres; Preferably, the intrinsic viscosity of the PLGA5050 is 0.15-0.35 dl / g, more preferably, the intrinsic viscosity of the PLGA5050 is 0.20-0.29 dl / g, and most preferably, the intrinsic viscosity of the PLGA5050 is 0.23-0.29 dl / g.
2. The breprazol microspheres according to claim 1, characterized in that: The molecular weight of the PLGA5050 is 8000-35000, preferably, the molecular weight of the PLGA5050 is 14000-35000, more preferably, the molecular weight of the PLGA5050 is 14000-25000 or 25000-35000.
3. The brepazine microspheres according to claim 1, characterized in that: The D50 of the microspheres is 20-100 μm, preferably, the D50 of the microspheres is 25-75 μm, more preferably, the D50 of the microspheres is 25-50 μm, and most preferably, the D50 of the microspheres is 25-45 μm.
4. The breprazol microspheres according to claim 1, characterized in that: The brepazine microspheres are of a core-shell structure, wherein the core comprises brepazine and the shell comprises PLGA5050; Preferably, the shell has an average thickness of 0.5-20 μm.
5. A method for preparing the brexpiprazole microspheres according to any one of claims 1 to 4, characterized in that: The method comprises the steps of: ① preparing a solution containing brepazole or its salt, PLGA5050 and an organic solvent; ② Under the condition of effectively inhibiting the evaporation of the organic solvent, mixing the solution obtained in step ① with the PVA solution to obtain an O / W emulsion; as well as ③ Under the condition that brepiraazole is precipitated in the form of spherical particles, the organic solvent in the O / W emulsion obtained in step ② is removed.
6. The method for preparing brepazine microspheres according to claim 5, characterized in that: In step ①, the organic solvent is selected from chloroform, dichloroethane, trichloroethane, dichloromethane, carbon tetrachloride, ether, isopropyl ether, ethyl acetate, butyl acetate, benzene, toluene, xylene, acetonitrile and mixtures thereof; preferably, the organic solvent is dichloromethane.
7. The method for preparing breprazol microspheres according to claim 5, characterized in that: In step ①, the volume weight ratio (mL / g) of the organic solvent to brepazine or its salt is 7:1-30:1; preferably, the volume weight ratio (mL / g) of the organic solvent to brepazine or its salt is 10:1-25:1; Preferably, in step ①, the weight ratio of PLGA5050 to brepazine or its salt is 4:1-1:4; more preferably, the weight ratio of PLGA5050 to brepazine or its salt is 1:1-1:
2.
8. The method for preparing breprazol microspheres according to claim 5, characterized in that: In step ②, the concentration of the PVA solution is 0.1%-3% (w / v).
9. The method for preparing breprazol microspheres according to claim 5, characterized in that: The step ③ also includes separation and freeze-drying steps.
10. An injectable aqueous suspension, characterized in that The suspension comprises the microspheres according to any one of claims 1 to 4 or the microspheres prepared by the method according to any one of claims 5 to 9, as well as a pharmaceutically acceptable carrier and water for injection; Preferably, the pharmaceutically acceptable carrier is selected from a suspending agent, a pH adjusting agent, an isotonicity adjusting agent, and a surfactant; Preferably, the suspending agent is selected from sodium carboxymethyl cellulose, polyvinyl alcohol, polyvinyl pyrrolidone, sodium alginate and glycerol; Preferably, the isotonicity adjusting agent is selected from sodium chloride, glucose, mannitol and sorbitol; Preferably, the pH adjuster is selected from citric acid, sodium hydroxide and disodium hydrogen phosphate; Preferably, the surfactant is a nonionic surfactant selected from the polysorbate series and the poloxamer series.
